Gilead Statement on Commitment to U.S. BioPharma Investments, Innovation and Affordability

Foster City, Calif., September 29, 2025 -Gilead Sciences reaffirms its commitment to develop solutions that make medicines more affordable for Americans, have other countries contribute a greater share, and increase investment in American innovation. As a leading U.S.-based company, Gilead plays a vital role in advancing the competitiveness of the U.S. healthcare system and delivering important breakthroughs that support American and global health priorities outlined in the Administration's health policy framework.

AN AMERICAN COMPANY: For over 35 years, Gilead has been proud to be an American company, reinvesting in the U.S. through innovation, jobs, and infrastructure. Nearly all of our R&D takes place in the U.S., where we employ more than 10,800 people. In 2025, we expect to contribute approximately $2.7 billion in federal and state taxes, with over 80% of our profits recognized in the U.S. and 90% of Gilead's income taxes paid to U.S. tax authorities.

DRIVING AMERICAN INNOVATION AND CREATING JOBS: We have committed $32 billion to U.S.-based innovation through 2030, projected to generate $43 billion in national economic valueover the next five years and create more than 3,000 direct and indirect jobs.

In addition to our current network of internal manufacturing sites in California and Maryland, construction is underway across multiple new Gilead facilities in Foster City, California, including:

• A new manufacturing technical development center broke ground in September 2025.
• A new Research Center will open in 2026.
• A new commercial launch manufacturing facility is set to begin construction next year.

Our partnerships extend the company's U.S. manufacturing footprint across more than a dozen states, including California, Colorado, Illinois, Ohio, Michigan, Massachusetts, North Carolina, Pennsylvania, Iowa, Washington, Florida, Wisconsin, and New Hampshire.

AMERICAN INNOVATIONS SOLVING HEALTH CHALLENGES: Gilead and the U.S. State Department recently announced a partnership to deploy the new life-saving HIV prevention medicine, lenacapavir, to high burden, low resources, HIV countries at no profit to the company in support of the America First Global Health Strategy. In the U.S., our breakthroughs in HIV prevention and treatment have dramatically reduced new infections and lowered long-term federal healthcare costs. Through its FOCUS program, Gilead is the nation's leading supporter of routine HIV screening, diagnosis, and linkage to care working with almost 200 partners around the country advancing the President's goal of ending the HIV epidemic in the United States by 2030.

Gilead developed the first FDA-approved treatment for COVID-19 and has led efforts to eliminate infectious diseases worldwide. Our breakthroughs innovations include therapies for hepatitis C, Ebola, and Marburg virus, and our R&D teams continue to prepare for future public health threats.

MAKING MEDICINES MORE AFFORDABLE FOR U.S. PATIENTS: Gilead helps individuals afford medicines through the company's free drug programs for uninsured individuals and co-pay assistance to minimize out-of-pocket costs for eligible patients. More than 550,000 individuals have received free Gilead medication through our free medication programs.

In 2024 and 2025, Gilead committed more than $300 million to advance community initiatives in the U.S., reflecting our deep and sustained investment in support of the health and well-being of Americans.

The company is actively engaging on innovative solutions like direct-to patient offerings for high volume, high rebate medicines that can reduce costs for Americans. PhRMA's new online platform will help connect patients directly with company-specific patient support and direct-to-patient offerings is a positive step forward to help U.S. patients identify and navigate to available programs and medicines.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information about Gilead, please visit the company's website at https://www.gilead.com, follow Gilead on X/Twitter (@Gilead Sciences) and LinkedIn (@Gilead-Sciences).